Incidence, Clearance, and Persistence of Anal Human Papillomavirus in Men Who Have Sex With Men Living With Human Immunodeficiency Virus: Implications for Human Papillomavirus Vaccination

Jason J. Ong, Sandra Walker, Andrew Grulich, Jennifer Hoy, Tim R.H. Read, Catriona Bradshaw, Marcus Chen, Suzanne M. Garland, Alyssa Cornall, Richard Hillman, David J. Templeton, Jane Hocking, Beng Eu, B. K. Tee, Eric P.F. Chow, Christopher K. Fairley

Research output: Contribution to journalArticleResearchpeer-review

Abstract

BACKGROUND: Men who have sex with men living with human immunodeficiency virus have a high risk of anal cancer. We estimate the likely benefit of human papillomavirus (HPV) vaccination among participants of the Anal Cancer Examination study. METHODS: Anal swabs were collected for the detection and genotyping of anal HPV DNA by linear array (Roche Diagnostics) in this 2-year multicenter prospective cohort. We calculated the proportion of men, stratified by age, without detectable vaccine type-specific DNA. RESULTS: Overall, 255 men, with a median age of 50 years (interquartile range, 44-56 years) contributed 488.9 person-years of follow-up. After 2 years of follow-up, 149 (58%; 95% confidence interval [CI], 52-65) had at least 1 high-risk HPV (HRHPV), and 71 (28%, 95% CI, 22-34) had HPV types 16/18 detected. Assuming that DNA-negative men would receive vaccine protection, vaccination at baseline could potentially prevent HRHPV infection in 10.2% of men (95% CI, 6.8-14.6, 26 of 255) 2 years later from incident HRHPV covered by the bivalent and quadrivalent vaccine, and 29.4% of men (95% CI, 23.9-35.4, 75/255) from incident HRHPV covered by the nonavalent vaccine. CONCLUSION: Though there is high prevalence of anal HPV in men who have sex with men living with human immunodeficiency virus, there was also a high incidence of HRHPV vaccine types in the 2-year follow-up, indicating potential for prevention if these men were not previously infected with HPV vaccine types and were vaccinated at their baseline visit.

Original languageEnglish
Pages (from-to)229-233
Number of pages5
JournalSexually Transmitted Diseases
Volume46
Issue number4
DOIs
Publication statusPublished - 1 Apr 2019

Cite this

Ong, Jason J. ; Walker, Sandra ; Grulich, Andrew ; Hoy, Jennifer ; Read, Tim R.H. ; Bradshaw, Catriona ; Chen, Marcus ; Garland, Suzanne M. ; Cornall, Alyssa ; Hillman, Richard ; Templeton, David J. ; Hocking, Jane ; Eu, Beng ; Tee, B. K. ; Chow, Eric P.F. ; Fairley, Christopher K. / Incidence, Clearance, and Persistence of Anal Human Papillomavirus in Men Who Have Sex With Men Living With Human Immunodeficiency Virus : Implications for Human Papillomavirus Vaccination. In: Sexually Transmitted Diseases. 2019 ; Vol. 46, No. 4. pp. 229-233.
@article{aacac07e91a64a08953b151bedcd6769,
title = "Incidence, Clearance, and Persistence of Anal Human Papillomavirus in Men Who Have Sex With Men Living With Human Immunodeficiency Virus: Implications for Human Papillomavirus Vaccination",
abstract = "BACKGROUND: Men who have sex with men living with human immunodeficiency virus have a high risk of anal cancer. We estimate the likely benefit of human papillomavirus (HPV) vaccination among participants of the Anal Cancer Examination study. METHODS: Anal swabs were collected for the detection and genotyping of anal HPV DNA by linear array (Roche Diagnostics) in this 2-year multicenter prospective cohort. We calculated the proportion of men, stratified by age, without detectable vaccine type-specific DNA. RESULTS: Overall, 255 men, with a median age of 50 years (interquartile range, 44-56 years) contributed 488.9 person-years of follow-up. After 2 years of follow-up, 149 (58{\%}; 95{\%} confidence interval [CI], 52-65) had at least 1 high-risk HPV (HRHPV), and 71 (28{\%}, 95{\%} CI, 22-34) had HPV types 16/18 detected. Assuming that DNA-negative men would receive vaccine protection, vaccination at baseline could potentially prevent HRHPV infection in 10.2{\%} of men (95{\%} CI, 6.8-14.6, 26 of 255) 2 years later from incident HRHPV covered by the bivalent and quadrivalent vaccine, and 29.4{\%} of men (95{\%} CI, 23.9-35.4, 75/255) from incident HRHPV covered by the nonavalent vaccine. CONCLUSION: Though there is high prevalence of anal HPV in men who have sex with men living with human immunodeficiency virus, there was also a high incidence of HRHPV vaccine types in the 2-year follow-up, indicating potential for prevention if these men were not previously infected with HPV vaccine types and were vaccinated at their baseline visit.",
author = "Ong, {Jason J.} and Sandra Walker and Andrew Grulich and Jennifer Hoy and Read, {Tim R.H.} and Catriona Bradshaw and Marcus Chen and Garland, {Suzanne M.} and Alyssa Cornall and Richard Hillman and Templeton, {David J.} and Jane Hocking and Beng Eu and Tee, {B. K.} and Chow, {Eric P.F.} and Fairley, {Christopher K.}",
year = "2019",
month = "4",
day = "1",
doi = "10.1097/OLQ.0000000000000958",
language = "English",
volume = "46",
pages = "229--233",
journal = "Sexually Transmitted Diseases",
issn = "0148-5717",
publisher = "Lippincott Williams & Wilkins",
number = "4",

}

Incidence, Clearance, and Persistence of Anal Human Papillomavirus in Men Who Have Sex With Men Living With Human Immunodeficiency Virus : Implications for Human Papillomavirus Vaccination. / Ong, Jason J.; Walker, Sandra; Grulich, Andrew; Hoy, Jennifer; Read, Tim R.H.; Bradshaw, Catriona; Chen, Marcus; Garland, Suzanne M.; Cornall, Alyssa; Hillman, Richard; Templeton, David J.; Hocking, Jane; Eu, Beng; Tee, B. K.; Chow, Eric P.F.; Fairley, Christopher K.

In: Sexually Transmitted Diseases, Vol. 46, No. 4, 01.04.2019, p. 229-233.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Incidence, Clearance, and Persistence of Anal Human Papillomavirus in Men Who Have Sex With Men Living With Human Immunodeficiency Virus

T2 - Implications for Human Papillomavirus Vaccination

AU - Ong, Jason J.

AU - Walker, Sandra

AU - Grulich, Andrew

AU - Hoy, Jennifer

AU - Read, Tim R.H.

AU - Bradshaw, Catriona

AU - Chen, Marcus

AU - Garland, Suzanne M.

AU - Cornall, Alyssa

AU - Hillman, Richard

AU - Templeton, David J.

AU - Hocking, Jane

AU - Eu, Beng

AU - Tee, B. K.

AU - Chow, Eric P.F.

AU - Fairley, Christopher K.

PY - 2019/4/1

Y1 - 2019/4/1

N2 - BACKGROUND: Men who have sex with men living with human immunodeficiency virus have a high risk of anal cancer. We estimate the likely benefit of human papillomavirus (HPV) vaccination among participants of the Anal Cancer Examination study. METHODS: Anal swabs were collected for the detection and genotyping of anal HPV DNA by linear array (Roche Diagnostics) in this 2-year multicenter prospective cohort. We calculated the proportion of men, stratified by age, without detectable vaccine type-specific DNA. RESULTS: Overall, 255 men, with a median age of 50 years (interquartile range, 44-56 years) contributed 488.9 person-years of follow-up. After 2 years of follow-up, 149 (58%; 95% confidence interval [CI], 52-65) had at least 1 high-risk HPV (HRHPV), and 71 (28%, 95% CI, 22-34) had HPV types 16/18 detected. Assuming that DNA-negative men would receive vaccine protection, vaccination at baseline could potentially prevent HRHPV infection in 10.2% of men (95% CI, 6.8-14.6, 26 of 255) 2 years later from incident HRHPV covered by the bivalent and quadrivalent vaccine, and 29.4% of men (95% CI, 23.9-35.4, 75/255) from incident HRHPV covered by the nonavalent vaccine. CONCLUSION: Though there is high prevalence of anal HPV in men who have sex with men living with human immunodeficiency virus, there was also a high incidence of HRHPV vaccine types in the 2-year follow-up, indicating potential for prevention if these men were not previously infected with HPV vaccine types and were vaccinated at their baseline visit.

AB - BACKGROUND: Men who have sex with men living with human immunodeficiency virus have a high risk of anal cancer. We estimate the likely benefit of human papillomavirus (HPV) vaccination among participants of the Anal Cancer Examination study. METHODS: Anal swabs were collected for the detection and genotyping of anal HPV DNA by linear array (Roche Diagnostics) in this 2-year multicenter prospective cohort. We calculated the proportion of men, stratified by age, without detectable vaccine type-specific DNA. RESULTS: Overall, 255 men, with a median age of 50 years (interquartile range, 44-56 years) contributed 488.9 person-years of follow-up. After 2 years of follow-up, 149 (58%; 95% confidence interval [CI], 52-65) had at least 1 high-risk HPV (HRHPV), and 71 (28%, 95% CI, 22-34) had HPV types 16/18 detected. Assuming that DNA-negative men would receive vaccine protection, vaccination at baseline could potentially prevent HRHPV infection in 10.2% of men (95% CI, 6.8-14.6, 26 of 255) 2 years later from incident HRHPV covered by the bivalent and quadrivalent vaccine, and 29.4% of men (95% CI, 23.9-35.4, 75/255) from incident HRHPV covered by the nonavalent vaccine. CONCLUSION: Though there is high prevalence of anal HPV in men who have sex with men living with human immunodeficiency virus, there was also a high incidence of HRHPV vaccine types in the 2-year follow-up, indicating potential for prevention if these men were not previously infected with HPV vaccine types and were vaccinated at their baseline visit.

UR - http://www.scopus.com/inward/record.url?scp=85063003489&partnerID=8YFLogxK

U2 - 10.1097/OLQ.0000000000000958

DO - 10.1097/OLQ.0000000000000958

M3 - Article

VL - 46

SP - 229

EP - 233

JO - Sexually Transmitted Diseases

JF - Sexually Transmitted Diseases

SN - 0148-5717

IS - 4

ER -